Home LiteratureArticle Details
PMID: 7568172 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 92 ·No. 21 ·1995-10-10 ·Pages 9560-4

Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, Mordes JP, Rossini AA

Abstract

Combined treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to CD40 ligand (CD40L) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet donors at major and minor histocompatibility loci. The effect of the allogeneic small lymphocytes was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-CD40L by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that small lymphocytes expressing donor antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-CD40L antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet grafts.

MeSH Terms
Animals Antigens, Differentiation, T-Lymphocyte/immunology CD40 Ligand Crosses, Genetic Diabetes Mellitus, Experimental/surgery Graft Survival Islets of Langerhans Transplantation/methods Lymphocyte Transfusion Membrane Glycoproteins/immunology Mice Mice, Inbred BALB C Mice, Inbred C3H Mice, Inbred C57BL Transplantation, Homologous
Chemicals
Antigens, Differentiation, T-Lymphocyte Membrane Glycoproteins CD40 Ligand
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Parker D C
Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester 01655, USA.
Greiner D L
Phillips N E
Appel M C
Steele A W
Durie F H
Noelle R J
Mordes J P
Rossini A A
References (45)
45 references, click to expand
  1. Recombinant CD40 ligand exerts potent biologic effects on T cells.
    J Immunol. 1994 May 1;152(9):4262-9 PMID: 7908915
  2. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.
    J Exp Med. 1993 Nov 1;178(5):1801-6 PMID: 8228826
  3. Induction of B cell costimulatory function by recombinant murine CD40 ligand.
    Eur J Immunol. 1994 Jan;24(1):116-23 PMID: 7517359
  4. The B7 and CD28 receptor families.
    Immunol Today. 1994 Jul;15(7):321-31 PMID: 7522010
  5. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis.
    J Immunol. 1994 Nov 1;153(9):4142-8 PMID: 7523517
  6. Activation of human dendritic cells through CD40 cross-linking.
    J Exp Med. 1994 Oct 1;180(4):1263-72 PMID: 7523569
  7. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes.
    Immunol Today. 1994 Oct;15(10):464-9 PMID: 7945770
  8. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.
    J Exp Med. 1994 Nov 1;180(5):1849-60 PMID: 7525841
  9. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2.
    Immunity. 1994 May;1(2):147-54 PMID: 7534198
  10. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.
    Immunity. 1994 Jun;1(3):167-78 PMID: 7534202
  11. Antigen presentation by resting B cells. Radiosensitivity of the antigen-presentation function and two distinct pathways of T cell activation.
    J Exp Med. 1984 Mar 1;159(3):881-905 PMID: 6607969
  12. B cells as antigen-presenting cells: the requirement for B cell activation.
    J Immunol. 1983 Jul;131(1):109-14 PMID: 6190900
  13. T cell receptor antagonists and partial agonists.
    Immunity. 1995 Jan;2(1):1-11 PMID: 7600296
  14. Major histocompatibility complex-restricted, polyclonal B cell responses resulting from helper T cell recognition of antiimmunoglobulin presented by small B lymphocytes.
    J Exp Med. 1985 Jan 1;161(1):223-41 PMID: 3155791
  15. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept.
    Annu Rev Immunol. 1983;1:143-73 PMID: 6443557
  16. A new member of the immunoglobulin superfamily--CTLA-4.
    Nature. 1987 Jul 16-22;328(6127):267-70 PMID: 3496540
  17. Characterization of antigen processing and presentation by resting B lymphocytes.
    J Immunol. 1988 Mar 1;140(5):1408-13 PMID: 3257975
  18. Veto cells.
    Annu Rev Immunol. 1988;6:115-37 PMID: 2898250
  19. Characterization of the effector mechanism of help for antigen-presenting and bystander resting B cell growth mediated by Ia-restricted Th2 helper T cell lines.
    J Immunol. 1988 Oct 1;141(7):2230-9 PMID: 2971722
  20. Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells.
    Nature. 1989 Jun 15;339(6225):541-4 PMID: 2525232
  21. Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft.
    J Immunol. 1989 Sep 1;143(5):1447-52 PMID: 2527264
  22. Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatch. Different mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity.
    Eur J Immunol. 1990 Feb;20(2):441-4 PMID: 2311650
  23. Autoimmune destruction of islets transplanted into RT6-depleted diabetes-resistant BB/Wor rats.
    Diabetes. 1990 May;39(5):643-5 PMID: 1970541
  24. The influence of allogeneic cells on the human T and B cell repertoire.
    Science. 1990 Jun 15;248(4961):1388-93 PMID: 1972596
  25. Approaching the asymptote? Evolution and revolution in immunology.
    Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13 PMID: 2700931
  26. Are primary alloresponses truly primary?
    Int Immunol. 1990;2(1):9-13 PMID: 1708274
  27. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway.
    Cell Immunol. 1991 Oct 15;137(2):429-37 PMID: 1716521
  28. Molecular and biological characterization of a murine ligand for CD40.
    Nature. 1992 May 7;357(6373):80-2 PMID: 1374165
  29. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.
    Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6550-4 PMID: 1378631
  30. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.
    Science. 1992 Aug 7;257(5071):789-92 PMID: 1323143
  31. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation.
    J Exp Med. 1992 Aug 1;176(2):407-13 PMID: 1500853
  32. B cells turn off virgin but not memory T cells.
    Science. 1992 Nov 13;258(5085):1156-9 PMID: 1439825
  33. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.
    Cell. 1992 Dec 24;71(7):1065-8 PMID: 1335362
  34. Proliferation of human T lymphocytes induced with superantigens is not dependent on costimulation by the CD28 counter-receptor B7.
    J Immunol. 1993 Feb 1;150(3):726-35 PMID: 7678619
  35. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
    J Exp Med. 1993 Apr 1;177(4):925-35 PMID: 7681471
  36. In situ expression of B7/BB1 on antigen-presenting cells and activated B cells: an immunohistochemical study.
    Int Immunol. 1993 Mar;5(3):317-21 PMID: 7682106
  37. T cell-dependent B cell activation.
    Annu Rev Immunol. 1993;11:331-60 PMID: 8476565
  38. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen.
    J Exp Med. 1993 May 1;177(5):1517-21 PMID: 8478622
  39. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40.
    J Exp Med. 1993 Aug 1;178(2):669-74 PMID: 7688031
  40. Regulation of expression of the ligand for CD40 on T helper lymphocytes.
    J Immunol. 1993 Aug 15;151(4):1777-88 PMID: 8102152
  41. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells.
    J Immunol. 1993 Sep 1;151(5):2497-510 PMID: 8103067
  42. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.
    Science. 1993 Sep 3;261(5126):1328-30 PMID: 7689748
  43. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.
    J Exp Med. 1993 Nov 1;178(5):1555-65 PMID: 7693849
  44. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.
    J Exp Med. 1993 Nov 1;178(5):1567-75 PMID: 7693850
  45. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.
    J Exp Med. 1994 Jul 1;180(1):157-63 PMID: 7516405
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
DOI
10.1073/pnas.92.21.9560
Published
1995-10-10
Pages
9560-4
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC40841
Subset
IM
Grants
NIDDK NIH HHS · DK25306 · United States
NIDDK NIH HHS · DK36024 · United States
NIDDK NIH HHS · DK41235 · United States
External Links
PubMed source DOI: 10.1073/pnas.92.21.9560 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2